Formation_of_neutralizing_antibodies_against_natural_interferon-beta,_but_not_against_recombinant_interferon-gamma_during_adjuvant_therapy_for_high-risk_malignant_melanoma_patients._In_an_adjuvant_clinical_trial,_34_high-risk_malignant_melanoma_patients_were_treated_with_natural_interferon_(IFN)-beta_and_recombinant_IFN-gamma._Patients_with_tumor_location_on_head,_neck,_and_trunk_received_3_million_IU_IFN-beta_intravenously_(IV)_three_times_weekly_for_24_weeks._Patients_with_tumor_location_on_the_extremities_received_subcutaneous_(SC)_injection_of_2_million_IU_of_IFN-beta_distal_the_locoregional_lymph_nodes_instead._All_patients_were_given_50_micrograms_IFN-gamma_SC_on_3_consecutive_days_every_4_weeks._Antibody_formation_was_detected_by_coincubation_of_IFN_and_patients'_serum_and_assessment_of_the_inhibition_of_the_cytopathic_effect_by_a_virus_suspension._Soluble_interleukin-2_receptors_(sIL-2R)_were_determined_by_enzyme-linked_immunosorbent_assay_(ELISA)_technique._No_antibodies_against_IFN-gamma_were_observed._The_overall_incidence_of_antibody_formation_to_IFN-beta_was_55.8%_(19/34)._Ninety-two_percent_of_the_SC-treated_patients_(13/14)_and_30%_(six_of_20)_of_the_IV-treated_patients_developed_antibodies._Soluble_interleukin-2_receptors_were_found_to_be_significantly_lower_in_antibody-positive_patients_than_in_antibody-negative_patients._The_authors_conclude_that_IFN-beta_antibody_formation_is_frequent_and_might_influence_IFN_induced_sIL-2R_elevation_in_vivo.